Resource Logo
CDC HIV/AIDS/Viral Hepatitis/STD/TB Prevention News Update

2 Firms to Pay HIV-Infected Hemophiliacs


Philadelphia Inquirer (08/03/94) P. A1

In a move that limits but does not completely eliminate future litigation against them, Rhone-Poulenc Rorer Inc. and Baxter International Inc. will contribute as much as $160 million to a fund for hemophiliacs who acquired HIV infection from blood- clotting products manufactured by the companies. As many as 6,000 infected individuals and their families are expected to apply for the compensation, according to David S. Shrager, lead counsel in the case. Filed in U.S. District Court in Chicago, the lawsuit alleges that Baxter, Rhone-Poulenc, and three other companies sold and promoted HIV-contaminated plasma proteins in the mid-1980s, even after learning of the risk involved. The plaintiffs charge that the companies did not adequately screen donors, test or treat plasma, or fully warn hemophiliacs about the risks. Three other firms accused- -Miles Inc., Alpha Therapeutic Corp., and the National Hemophilia Foundation--opted not to participate in the settlement. Related Stories: Wall Street Journal (08/03) P. B7; New York Times (08/03) P. A22; Baltimore Sun (08/03) P. 2A


Copyright © 1994 -CDC Prevention News Update, Publisher. All rights reserved to Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

Information in this article was accurate in August 3, 1994. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.